Comparative cost-utility analysis of ixekizumab, tofacitinib, and golimumab in psoriatic arthritis: a real-world Markov model simulation
Expert Review of Pharmacoeconomics & Outcomes Research · 2026
DOI: 10.1080/14737167.2026.2629351 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2026. Verfasst von Rubén Queiro und 5 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Division, Central University Hospital of Asturias, Oviedo, Spain. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Piperidines, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Psoriatic arthritis (PsA) requires long-term, phenotype-oriented management. This study compared the cost-utility of ixekizumab, tofacitinib, and golimumab using a real-world modeling approach. RESEARCH DESIGN AND METHODS: A 10-year Markov model was developed from the perspective of the Spanish National Health System, informed by three real-world PsA cohorts. Transition probabilities were derived from drug-persistence data. Utilities and direct medical costs were obtained from published sources. Approved dosing, standard treatment durations, and annual cycles were modeled. Main outcomes included total costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs). Scenario analyses evaluated a 20% price reduction and phenotype-specific settings (enthesitis, dactylitis, axial PsA, refractory disease, prior TNFi failure, and relevant comorbidity). RESULTS: All three agents were cost-effective in the base case, with ICERs below the €30,000/QALY threshold. Ixekizumab provided the highest QALYs and was most cost-effective in axial PsA, enthesitis, and refractory disease. Tofacitinib, with the lowest total cost, was dominant in TNFi-failure scenarios. Golimumab offered the best value in dactylitis and comorbid patients and showed marked improvement under reduced-price conditions. Safety-related discontinuations were infrequent across cohorts. CONCLUSIONS: Ixekizumab, tofacitinib, and golimumab are all cost-effective options for PsA. These findings support phenotype-guided therapeutic decisions and highlight the influence of drug pricing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rheumatology Division, Central University Hospital of Asturias, Oviedo, Spain.
- Department of Medicine, Oviedo University School of Medicine, Oviedo, Spain.
- Translational Immunology Division, Health Research Institute of the Principality of Asturias (ISPA), Oviedo, Spain.
ORCID-Profile: Rubén Queiro
Zitieren
APA
Queiro, R., Braña, I., Alvarez, P., Loredo, M., Pardo, E., & Burger, S. (2026). Comparative cost-utility analysis of ixekizumab, tofacitinib, and golimumab in psoriatic arthritis: a real-world Markov model simulation. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2026.2629351
Vancouver
Queiro R, Braña I, Alvarez P, Loredo M, Pardo E, Burger S. Comparative cost-utility analysis of ixekizumab, tofacitinib, and golimumab in psoriatic arthritis: a real-world Markov model simulation. Expert Review of Pharmacoeconomics & Outcomes Research. 2026. doi:10.1080/14737167.2026.2629351
BibTeX
@article{Queiro2026,
author = {Queiro, Rubén and Braña, Ignacio and Alvarez, Paula and Loredo, Marta and Pardo, Estefanía and Burger, Stefanie},
title = {Comparative cost-utility analysis of ixekizumab, tofacitinib, and golimumab in psoriatic arthritis: a real-world Markov model simulation},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2026},
doi = {10.1080/14737167.2026.2629351}
}
EUVIMED